Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Orchestra BioMed is a pre-revenue medical device company developing two lead products: BackBeat Cardiac Neuromodulation Therapy (CNT) for hypertension treatment and Virtue Sirolimus AngioInfusion Balloon (SAB) for peripheral artery disease. The company operates through a partnership model with Terumo Corporation for BackBeat and maintains direct development of Virtue SAB, targeting multi-billion dollar addressable markets in cardiovascular interventions.
Orchestra operates a hybrid commercialization model: BackBeat CNT is partnered with Terumo Corporation, which provides development funding and will handle commercialization in exchange for Orchestra receiving milestone payments and royalties on sales. Virtue SAB is being developed independently for direct commercialization, targeting the $2+ billion drug-coated balloon market for peripheral artery disease. The company's value proposition centers on differentiated mechanisms of action - BackBeat uses cardiac neuromodulation rather than traditional antihypertensive drugs, while Virtue SAB delivers sirolimus via a unique balloon catheter design. Pricing power will depend on clinical differentiation versus existing therapies and reimbursement dynamics in cardiovascular interventions.
BackBeat CNT pivotal trial enrollment progress and interim data readouts (BAROSTIM HTN-2 trial targeting 300+ patients)
Virtue SAB clinical trial results and regulatory submission timelines (VIRTUE trial data expected in 2026-2027 timeframe)
FDA regulatory interactions and approval pathway clarity for both devices
Terumo partnership milestone achievements and potential expansion of collaboration terms
Cash runway updates and financing activities given $23.5% negative FCF yield
Regulatory approval risk for novel mechanisms of action - BackBeat CNT represents new therapeutic category requiring extensive safety/efficacy data, while Virtue SAB competes in crowded drug-coated balloon market with established competitors (Medtronic IN.PACT, BD Lutonix)
Reimbursement uncertainty for BackBeat CNT given lack of precedent for cardiac neuromodulation in hypertension - CMS coverage decisions could significantly impact commercial viability
Clinical trial execution risk with small company infrastructure managing two complex pivotal programs simultaneously
Virtue SAB faces entrenched competition from Medtronic, Boston Scientific, and BD in peripheral drug-coated balloons with established physician relationships and clinical evidence
BackBeat CNT competes indirectly with renal denervation technologies (Medtronic Symplicity, ReCor Paradise) and established antihypertensive pharmaceutical regimens
Terumo partnership concentration risk - 50%+ of value dependent on single partner's commercialization execution and strategic priorities
Severe cash burn with -$23.5% FCF yield and estimated 12-18 month runway requires near-term capital raise, likely dilutive to current shareholders
Small market cap of $200 million limits access to institutional capital and creates liquidity risk for investors
Negative ROE of -320% and ROA of -71.7% reflect substantial accumulated deficit and ongoing losses - path to profitability requires successful commercialization 5+ years out
low - Medical device development timelines are largely insulated from economic cycles, as clinical trials and regulatory processes follow predetermined schedules. However, capital markets conditions significantly impact ability to raise funding for cash-burning clinical-stage companies. Hospital capital equipment budgets for cardiovascular devices can be affected during severe recessions, potentially impacting future commercial adoption.
Rising interest rates negatively impact Orchestra through two channels: (1) Higher discount rates compress NPV of future cash flows for pre-revenue biotechs, disproportionately affecting valuation given 5-7 year timeline to potential commercialization; (2) Tighter financial conditions reduce access to growth equity capital, critical for funding $25-30 million annual burn rate with current 4.73x current ratio providing approximately 12-18 months of runway at current burn. Rate increases also elevate opportunity cost for speculative biotech investments versus risk-free alternatives.
Minimal direct credit exposure given negligible debt (0.04x D/E ratio) and no commercial operations requiring working capital financing. However, credit market conditions indirectly affect ability to raise capital through convertible debt or venture debt facilities, which are common financing tools for clinical-stage medical device companies. Tightening credit spreads can limit financing options and increase dilution risk.
growth - Attracts speculative biotech investors and venture-style public market funds willing to underwrite binary regulatory outcomes with 3-5x return potential on successful approval. Not suitable for value or income investors given pre-revenue status, negative margins, and no dividend. Requires high risk tolerance and long investment horizon. Recent 49.4% six-month return followed by -34.8% one-year return demonstrates event-driven volatility around clinical/regulatory catalysts.
high - Small-cap pre-revenue biotech with binary clinical trial and regulatory outcomes creates extreme volatility. Stock moves 20-40% on trial data releases or FDA interactions. Low trading volume and $200 million market cap amplify price swings. Estimated beta above 1.5x relative to broader biotech indices.
